2023 World Conference on Lung Cancer (Posters)-P2.05. Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts

P2.05. Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses a study on the use of serum metabolomics as a biomarker for determining the survival of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). The study focused on the metabolomic profile as a means of distinguishing long-term survival from short-term survival in NSCLC patients treated with immune checkpoint inhibitors (ICIs). <br /><br />The study recruited 97 patients with stage IV NSCLC who received anti-PD-1 inhibitors as either second-line or first-line treatment. Blood samples were collected before starting immunotherapy, and serum metabolomic profiling was performed using UHPLC-Q-TOF MS analysis. Multivariate data analysis techniques were applied to analyze the data.<br /><br />The results revealed 41 differential metabolites in Cohort 1 (second-line treatment) and 47 differential metabolites in Cohort 2 (first-line treatment). The analysis identified several common metabolites significantly associated with both progression-free survival (PFS) and overall survival (OS). Additionally, specific metabolic pathways were found to be enriched in the long-term survival group compared to the short-term survival group.<br /><br />The top three enriched KEGG pathways in Cohort 1 were primary bile acid biosynthesis, african trypanosomiasis, and choline metabolism in cancer. In Cohort 2, the top three enriched KEGG pathways were the citrate cycle, PPAR signaling pathway, and primary bile acid biosynthesis. Notably, the analysis indicated a significant difference in the primary bile acid synthesis pathway between the long-term and short-term survival groups in both cohorts.<br /><br />In conclusion, this study suggests that analyzing peripheral blood metabolomics is crucial for identifying metabolic biomarkers and pathways associated with NSCLC patients treated with ICIs. The primary bile acid synthesis pathway may play a significant role in determining the effectiveness of immunotherapy. The findings highlight the potential of metabolomic profiling as a noninvasive approach for identifying patients who are more likely to achieve long-term survival with immunotherapy.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

serum metabolomics

biomarker

immunotherapy

non-small cell lung cancer

NSCLC

immune checkpoint inhibitors

UHPLC-Q-TOF MS analysis

progression-free survival

overall survival

metabolic pathways